Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lyophilized human rabies vaccine (human diploid cell)** is a prophylactic rabies vaccine being developed by **Bohui Instrument Group** for the prevention of rabies in humans. It is described in Bohui's pipeline as a **lyophilized vaccine produced in human diploid cells** and is intended to provide **active immunization** by exposing recipients to rabies virus antigens, thereby inducing protective neutralizing antibody and adaptive immune responses that prevent rabies infection after exposure risk. Based on the company pipeline disclosures provided, the program had received IND approval and was positioned to enter **Phase 1** clinical development for **rabies prevention**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lyophilized human rabies vaccine.